

LFW

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on December 14, 2004.

[Signature]

Doran R. Pace, Patent Attorney

INFORMATION DISCLOSURE
STATEMENT

Examining Group 1645
Patent Application
Docket No. USF-T190XC1
Serial No. 10/766,157

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1645
Applicants : Thomas P. Loughran, Jr., Ravi Kothapalli
Serial No. : 10/766,157
Filed : January 28, 2004
Conf. No. : 5993
For : Differentially Expressed Genes in Large Granular Lymphocyte Leukemia

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:


In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, Applicants have not submitted copies of the U.S. published patent applications cited on attached Form PTO/SB/08 pursuant to the Notice at 1276 OG 55 waiving the requirement set forth at 37 CFR 1.98(a)(2)(i).

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

BEST AVAILABLE COPY

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.


Respectfully submitted,



Doran R. Pace
Patent Attorney
Registration No. 38,261
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

DRP/sl

Attachments: Form PTO/SB/08; copies of references cited therein.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/766,157
Filing Date	January 28, 2004
First Named Inventor	Thomas P. Loughran, Jr.
Art Unit	1645
Examiner Name	
Attorney Docket Number	USF-T190XC1

Sheet

1

of

4

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-2003/0190654	10/09/2003	Heidenreich <i>et al.</i>	All
	U2	US-2003/0032594	02/13/2003	Bonny	All
	U3	US-2002/0120100	08/29/2002	Bonny	All
	U4	US-2002/0035243	03/21/2002	Imfeld <i>et al.</i>	All
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 01/36646 A1	05/25/2001	Cancer Research Campaign Technology Limited	All	
	F2	WO 02/057311 A2	07/25/2002	University of South Florida	All	
	F3	WO 99/09206 A1	02/25/1999	Blood Research Center	All	
	F4					
	F5					
	F6					

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/766,157		
		Filing Date	January 28, 2004		
		First Named Inventor	Thomas P. Loughran, Jr.		
		Group Art Unit	1645		
		Examiner Name			
Sheet	2	of	4	Attorney Docket Number	USF-T190XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	item (book, T ²
	R1	CALLAN, M. <i>et al.</i> "CD8* T-cell selection, function, and death in the primary immune response in vivo" <i>The Journal of Clinical Investigation</i> , November 2000, pp. 1251-1261, Vol. 106, No. 10.	
	R2	LOUGHRAN, T. P. JR. "Clonal Diseases of Large Granular Lymphocytes" <i>Blood</i> , July 1, 1993, pp. 1-14, Vol. 82, No. 1.	
	R3	OSHIMI, K. <i>et al.</i> "Perforin Gene Expression in Granular Lymphocyte Proliferative Disorders" <i>Blood</i> , February 1, 1990, pp. 704-708, Vol. 75, No. 3.	
	R4	LOUGHRAN, T. P. JR. <i>et al.</i> "Anti-CD3 Monoclonal Antibody-Mediated Cytotoxicity Occurs Through an Interleukin-2-Independent Pathway in CD3+ Large Granular Lymphocytes" <i>Blood</i> , February 15, 1990, pp. 935-940, Vol. 75, No. 4.	
	R5	LAMY, T. <i>et al.</i> "Dysregulation of CD95/CD95 Ligand-Apoptotic Pathway in CD3* Large Granular Lymphocyte Leukemia" <i>Blood</i> , December 15, 1998, pp. 4771-4777, Vol. 92, No. 12.	
	R6	KASTEN-SPORTES, C. <i>et al.</i> "T-Cell Receptor Gene Rearrangement in T-Cell Large Granular Leukocyte Leukemia: Preferential V α but Diverse J α Usage in One of Five Patients" <i>Blood</i> , February 1, 1994, pp. 767-775, Vol. 83, No. 3.	
	R7	HOSHINO, S. <i>et al.</i> "Activation via the CD3 and CD16 Pathway Mediates Interleukin-2-Dependent Autocrine Proliferation of Granular Lymphocytes in Patients With Granular Lymphocyte Proliferative Disorders" <i>Blood</i> , December 15, 1991, pp. 3232-3240, Vol. 78, No. 12.	
	R8	DAIBATA, M. <i>et al.</i> "Differential Gene-Expression Profiling in the Leukemia Cell Lines Derived From Indolent And Aggressive Phases of CD56* T-Cell Large Granular Lymphocyte Leukemia" <i>Int. J. Cancer</i> , 2004, pp. 845-851, Vol. 108.	
	R9	MAKISHIMA, H. <i>et al.</i> "DNA microarray analysis of T cell-type lymphoproliferative disease of granular lymphocytes" <i>British Journal of Haematology</i> , 2002, pp. 462-469, Vol. 118.	
	R10	KOTHAPALLI, R. <i>et al.</i> "Constitutive expression of cytotoxic proteases and down-regulation of protease inhibitors in LGL leukemia" <i>International Journal of Oncology</i> , January 1, 2003, pp. 33-39, Vol. 22, No. 1.	
	R11	PERZOVA, R. <i>et al.</i> "Constitutive expression of Fas ligand in large granular lymphocyte leukaemia" <i>British Journal of Haematology</i> , 1997, pp. 123-126, Vol. 97.	
	R12	WESTON, G. S. <i>et al.</i> "Granzymes as Potential Targets for Rational Drug Design" <i>Current Medicinal Chemistry</i> , 1996, pp. 37-46, Vol. 3.	
	R13	EPSTEIN, C. B. <i>et al.</i> "Microarray technology - enhanced versatility, persistent challenge" <i>Current Opinion In Biotechnology</i> , February 1, 2000, pp. 36-41, Vol. 11, No. 1.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/766,157		
		Filing Date	January 28, 2004		
		First Named Inventor	Thomas P. Loughran, Jr.		
		Group Art Unit	1645		
		Examiner Name			
Sheet	3	of	4	Attorney Docket Number	USF-T190XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	item (book, T ²
	R14	MCMANUS, M. T. <i>et al.</i> "Gene Silencing In Mammals By Small Interfering RNAs" <i>Nature Reviews Genetics</i> , October 2002, pp. 737-747, Vol. 3.	
	R15	TAKASHITA, E. <i>et al.</i> "Destruction of hematopoietic microenvironment by cytotoxic T cells" <i>Experimental Hematology</i> , 1997, pp. 1034-1041, Vol. 25, No. 10.	
	R16	CRABTREE, G. R. <i>et al.</i> "Signal transmission between the plasma membrane and nucleus of T lymphocytes" <i>Ann Rev Biochem</i> , 1994, pp. 1045-1083, Vol. 63.	
	R17	BUTZ, E. A. <i>et al.</i> "Massive expansion of antigen-specific CD8+ T cells during an acute virus infection" <i>Immunity</i> , 1998, pp. 167-175, Vol. 8.	
	R18	ENGLER-BLUM, G. <i>et al.</i> "Reduction of background in problems in non-radioactive Northern blot analysis enables higher sensitivity than ³² P-based hybridizations" <i>Anal. Biochem</i> , 1993, pp. 235-244, Vol. 210.	
	R19	GRAKOU, A. <i>et al.</i> "The immunological synapse: a molecular machine controlling T-cell activation" <i>Science</i> , 1999, pp. 221-227, Vol. 285.	
	R20	KOTHAPALLI, R. <i>et al.</i> "Microarray results: how accurate are they?" <i>BMC Bioinformatics</i> , 2002, pp. 1-10, Vol. 3.	
	R21	KOTHAPALLI, R. <i>et al.</i> "Characterization of a human sphingosine-1-phosphate receptor gene (<i>SIP₃</i>) and its differential expression in LGL leukemia" <i>Biochimica et Biophysica Acta</i> , 2002, pp. 117-123, Vol. 1579.	
	R22	KOTHAPALLI, R. <i>et al.</i> "Characterization of a variant of PAC-1 in large granular lymphocyte leukemia" <i>Protein Expression & Purification</i> , 2003, pp. 52-60, Vol. 32.	
	R23	LAMY, T. <i>et al.</i> "Current concepts: large granular lymphocyte leukemia" <i>Blood Rev.</i> , 1999, pp. 230-240, Vol. 13.	
	R24	NAGATA, S. <i>et al.</i> "The Fas death factor" <i>Science</i> , 1995, pp. 1449-1456, Vol. 267.	
	R25	ZAMBELLO, R. <i>et al.</i> "Analysis of the T Cell Receptor in the Lymphoproliferative Disease of Granular Lymphocytes: Superantigen Activation of Clonal CD3+ Granular Lymphocytes" <i>Cancer Res.</i> , 1995, pp. 6140-6145, Vol. 55.	
	R26	ZIMMERMANN, C. <i>et al.</i> , "Homeostatic regulation of CD8+ T Cells after antigen challenge in the absence of Fas (CD95)" <i>Eur. J. Immunol.</i> , 1996, pp. 2903-2910, Vol. 26.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/766,157
Filing Date	January 28, 2004
First Named Inventor	Thomas P. Loughran, Jr.
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	USF-T190XC1

Sheet	4	of	4
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	item (book, T ²
	R27	KOO, G. C. <i>et al.</i> "Association of Serine Protease with the Rise of Intracellular Calcium in Cytotoxic T Lymphocytes" <i>Cellular Immunology</i> , 1996, pp. 107-115, Vol. 174, Article No. 0300.	
	R28		
	R29		
	R30		
	R31		
	R32		
	R33		
	R34		
	R35		
	R36		
	R37		
	R38		
	R39		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.